Crinetics Pharmaceuticals (CRNX) Tops Q2 EPS by 8c
Tweet
Share
E-mailGet Alerts CRNX Hot Sheet
Join SI Premium – FREE
Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q2 EPS of ($1.14), $0.08 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $25.12 million versus the consensus estimate of $14.87 million.
For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- Airbnb Inc. (ABNB) PT Raised to $200 at Baird
- Palantir and Nebius partner on sovereign AI infrastructure
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
